AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Imbruvica (ibrutinib) by Quarter
Imbruvica (ibrutinib) — International operational (constant-currency) growth YoY (%) (%)
AbbVie Imbruvica (ibrutinib): -7.8% in Q2 2026, up 3.4 pts from a year earlier.
Latest, Q2 2026
-7.8%
Period ended Jun 30, 2026
Change on a year earlier
+3.4 pts
-11.2% in Q2 2025
History
35 quarters
Since Q4 2017
Sources
35
Documents cited below
Where the Q2 2026 figure comes from
“|| Imbruvica b | 337 | 195 | 532 | (37.8) | (7.8) | (29.4) | (7.8) | (29.4)”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Imbruvica (ibrutinib) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/imbruvica-intl-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.